2026-10-13T06:28:33Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34045611 2026-10-01T12:15:11Z category_696 portal_316 item_type_1 month_year_10_2026

Image 2_Spatial immune ecosystems and therapy resistance in large B-cell lymphoma: from single-cell multi-omics to immunotherapy-matched validation.tiff Gaojie Liu (9133553) Junwei Yang (112231) Han Li (10885) Lishuo Deng (25152123) Liuxin Jiang (25152120) Yuetong Tan (25152126) Jianxiong Zhu (5321027) Jifan Li (6498407) Yao Wang (102387) Genetic Immunology antibody-drug conjugates bispecific antibodies cancer immunotherapy CAR-T cells diffuse large B-cell lymphoma large B-cell lymphoma pathology-ready biomarkers spatial immunology <p>Large B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), provide a clinically important model in which tumor-intrinsic programs, immune recognition, effector-cell fitness, and tissue architecture jointly shape response and resistance to immunotherapy. Although molecular classification has refined the understanding of lymphoma biology, relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cell therapy, CD20×CD3 bispecific antibodies, antibody-drug conjugates (ADCs), and immune-combination strategies cannot be explained by genetics or target-antigen expression alone. Single-cell and spatial multi-omics now allow lymphoma to be interpreted as a spatial immune ecosystem composed of malignant B-cell states, exhausted or regulatory T-cell programs, myeloid suppressive hubs, stromal and vascular compartmentalization, metabolic gradients, and local communication networks. This Review synthesizes recent DLBCL and large B-cell lymphoma ecosystem studies from a cancer-immunology perspective, emphasizing how spatial immune organization may influence effector access, antigen engagement, macrophage-mediated suppression, antibody exposure, and treatment-associated spatial change. We propose a treatment-matched validation framework that connects high-dimensional discovery to formalin-fixed paraffin-embedded (FFPE)-compatible pathology assays, including reduced marker panels for CAR T-cell therapy, bispecific antibodies, ADC-containing therapy, and immune-combination trials. Throughout, we distinguish observed tissue organization from computationally inferred communication and experimentally validated mechanisms. The resulting framework is intended as a trial-design and biomarker-development roadmap, not as a current clinical allocation algorithm.</p> 2026-10-01T12:15:11Z Image Figure 10.3389/fimmu.2026.1916056.s003 https://figshare.com/articles/figure/Image_2_Spatial_immune_ecosystems_and_therapy_resistance_in_large_B-cell_lymphoma_from_single-cell_multi-omics_to_immunotherapy-matched_validation_tiff/34045611 CC BY 4.0